ブレポシチニブの市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

ブレポシチニブは、ファーストインクラスのTYK2とJAK1の二重阻害薬であり、これはTYK2またはJAK1を単独で阻害する薬剤よりも、複数の炎症性の高い自己免疫疾患に対してより高い有効性が予測される新規の作用機序です。経口ブレポシチニブは、5つのプラセボ対照フェーズII試験を含む、15件のフェーズIおよびフェーズII試験が終了しています。5つのプラセボ対照フェーズII試験全てにおいて、統計学的に有意かつ臨床的に意義のある有効性の結果が得られています。

当レポートでは、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）における炎症性筋疾患（IM）向けブレポシチニブについて調査分析し、市場規模の予測や、作用機序、用法と用量、研究開発活動などの情報を提供しています。

目次

第1章 レポートのイントロダクション

第2章 炎症性筋疾患（IM）におけるブレポシチニブの概要

• 製品詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期段階の新治療法）

第5章 ブレポシチニブ市場の評価

• 炎症性筋疾患（IM）におけるブレポシチニブの市場見通し
• 主要7市場の分析
  • 主要7市場の炎症性筋疾患（IM）向けブレポシチニブの市場規模
• 市場の分析：国別
  • 米国の炎症性筋疾患（IM）向けブレポシチニブの市場規模
  • ドイツの炎症性筋疾患（IM）向けブレポシチニブの市場規模
  • 英国の炎症性筋疾患（IM）向けブレポシチニブの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Brepocitinib, Clinical Trial Description, 2023
• Table 2: Brepocitinib, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Brepocitinib Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Brepocitinib Market Size in the US, in USD million (2019-2032)
• Table 7: Brepocitinib Market Size in Germany, in USD million (2019-2032)
• Table 8: Brepocitinib Market Size in France, in USD million (2019-2032)
• Table 9: Brepocitinib Market Size in Italy, in USD million (2019-2032)
• Table 10: Brepocitinib Market Size in Spain, in USD million (2019-2032)
• Table 11: Brepocitinib Market Size in the UK, in USD million (2019-2032)
• Table 12: Brepocitinib Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Brepocitinib Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Brepocitinib Market Size in the United States, USD million (2019-2032)
• Figure 3: Brepocitinib Market Size in Germany, USD million (2019-2032)
• Figure 4: Brepocitinib Market Size in France, USD million (2019-2032)
• Figure 5: Brepocitinib Market Size in Italy, USD million (2019-2032)
• Figure 6: Brepocitinib Market Size in Spain, USD million (2019-2032)
• Figure 7: Brepocitinib Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Brepocitinib Market Size in Japan, USD million (2019-2032)

"Brepocitinib Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Brepocitinib for Inflammatory Myositis (IM) in the seven major markets. A detailed picture of the Brepocitinib for IM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Brepocitinib for IM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Brepocitinib market forecast analysis for IM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in IM.

Drug Summary:

Brepocitinib is a potential first-in-class dual inhibitor of TYK2 and JAK1, a novel mechanism of action expected to potentially provide greater efficacy in multiple highly inflammatory autoimmune diseases than agents that inhibit either TYK2 or JAK1 alone. Oral brepocitinib has been evaluated in 15 completed Phase I and Phase II studies, including five placebo-controlled Phase II studies. All five placebo-controlled Phase II studies generated statistically significant and clinically meaningful efficacy results.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Brepocitinib description, mechanism of action, dosage and administration, research and development activities in Inflammatory Myositis (IM).
• Elaborated details on Brepocitinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Brepocitinib research and development activities in IM across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Brepocitinib.
• The report contains forecasted sales of Brepocitinib for IM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for IM.
• The report also features the SWOT analysis with analyst views for Brepocitinib in IM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Brepocitinib Analytical Perspective by DelveInsight

• In-depth Brepocitinib Market Assessment

This report provides a detailed market assessment of Brepocitinib for Inflammatory Myositis (IM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Brepocitinib Clinical Assessment

The report provides the clinical trials information of Brepocitinib for Inflammatory Myositis (IM) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Inflammatory Myositis (IM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Brepocitinib dominance.
• Other emerging products for IM are expected to give tough market competition to Brepocitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Brepocitinib in IM.
• Our in-depth analysis of the forecasted sales data of Brepocitinib from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Brepocitinib in IM.

Key Questions:

• What is the product type, route of administration and mechanism of action of Brepocitinib?
• What is the clinical trial status of the study related to Brepocitinib in Inflammatory Myositis (IM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Brepocitinib development?
• What are the key designations that have been granted to Brepocitinib for IM?
• What is the forecasted market scenario of Brepocitinib for IM?
• What are the forecasted sales of Brepocitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Brepocitinib for IM?
• Which are the late-stage emerging therapies under development for the treatment of IM?

Table of Contents

1. Report Introduction

2. Brepocitinib Overview in Inflammatory Myositis (IM)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Brepocitinib Market Assessment

• 5.1. Market Outlook of Brepocitinib in Inflammatory Myositis (IM)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Brepocitinib in the 7MM for Inflammatory Myositis (IM)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Brepocitinib in the United States for Inflammatory Myositis (IM)
  • 5.3.2. Market Size of Brepocitinib in Germany for Inflammatory Myositis (IM)
  • 5.3.3. Market Size of Brepocitinib in France for Inflammatory Myositis (IM)
  • 5.3.4. Market Size of Brepocitinib in Italy for Inflammatory Myositis (IM)
  • 5.3.5. Market Size of Brepocitinib in Spain for Inflammatory Myositis (IM)
  • 5.3.6. Market Size of Brepocitinib in the United Kingdom for Inflammatory Myositis (IM)
  • 5.3.7. Market Size of Brepocitinib in Japan for Inflammatory Myositis (IM)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options